奇利辛囊通过调节miR-382-5p/ATF3轴来缓解心脏缩和心脏功能障碍
Bao Yin1, XiaoTong Jiang1, XinFeng Chang2
1Department of Cardiovascular, Zibo Hospital of Traditional Chinese Medicine, Zibo City, Shandong Province, China.
Clinics (Sao Paulo, Brazil)
|September 27, 2024
概括
奇利辛囊 (QL) 可以通过调节miR-382-5p/ATF3通路来治疗心脏缩. 这项研究表明,QL可以缓解小鼠和心肌细胞的心脏功能障碍和过度缩小.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏缩是心力衰竭的重要危险因素.
- 了解心脏缩背后的分子机制对于开发有效治疗方法至关重要.
研究的目的:
- 调查Qiliqiangxin囊 (QL) 对心脏缩的潜在治疗作用.
- 阐明分子机制,特别是参与QL作用的miR-382-5p/ATF3轴的作用.
主要方法:
- 新生小鼠室内心肌细胞 (NMVCs) 用 ангиотензин II (Ang-II) 进行治疗,以诱导缩.
- QL作为NMVC和心脏缩的体内小鼠模型的预治疗.
- 评估了心肌细胞表面积,高缩标志物 (ANP,BNP),心脏功能 (心声图),以及分子标 (miR-382-5p,ATF3).
主要成果:
- 由Ang-II诱导的心肌细胞缩,由细胞表面积增加和ANP/BNP水平升高证明.
- 在细胞和动物模型中,QL治疗减轻了Ang-II诱导的缩和心脏功能障碍.
- QL抑制了miR-382-5p的表达,这反过来调节了激活转录因子3 (ATF3) 的表达,这表明该轴的关键作用.
结论:
- 奇利辛囊表现出对心脏缩和功能障碍的保护作用.
- QL的治疗机制涉及对miR-382-5p/ATF3信号通路的调制.
- QL具有作为治疗心脏缩和相关心脏功能障碍的治疗剂的潜力.
更多相关视频
10:05Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
8.7K
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.2K
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395